Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 219.95B |
| Revenue (ttm) | 41.82B |
| Net Income (ttm) | 14.89B |
| Shares Out | n/a |
| EPS (ttm) | 3.35 |
| PE Ratio | 14.77 |
| Forward PE | 15.66 |
| Dividend | 1.56 (3.25%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 557,867 |
| Average Volume | 384,403 |
| Open | 50.39 |
| Previous Close | 49.36 |
| Day's Range | 49.74 - 53.36 |
| 52-Week Range | 38.51 - 121.50 |
| Beta | 0.32 |
| RSI | 66.92 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Novo Nordisk shares climb after positive results for anti-obesity pill
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss' with tablet version of Wegovy
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk A/S NVO looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is startin...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closer
Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upc...
It Is Time To Buy Novo Nordisk Hand Over Fist
Novo Nordisk A/S remains a Strong Buy, driven by restructuring, pipeline advancements, and robust product developments like the Wegovy pill. NVO's restructuring will cut 9,000 jobs, saving $1.27B annu...
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit - NVO
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk shares rise 5% on upbeat analyst reaction to diabetes conference
Novo Nordisk shares rose 5% on Thursday following positive analyst reactions to an investor meeting that company executives held at the European Association for the Study of Diabetes conference.
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.
In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semagluti...
Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds
Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.
Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment ...
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK , Sept. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025...
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Novo Nordisk A/S - Special Call
Novo Nordisk A/S - Special Call Company Participants Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Martin Parkhoi - SEB, Research Division Michael Novo...
Novo Nordisk says Wegovy pill shows comparable weight-loss to injectable version
Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The New England Journal of Medicine on Wednesday, which is comparable to previo...
Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the inves...
NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2...
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa , Sept. 17, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say.
GLP-1 drugs could save millions of lives — and spark a pension crisis
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, o...